Despite an initial complete response letter and a challenging bout with members of the Arthritis Advisory Committee and FDA reviewers, Eli Lilly and Co. and licensor Incyte Corp. have gained the agency's approval for a 2-mg dose of the once-daily oral JAK 1/2 inhibitor baricitinib, the lower of two doses the partners have sought to market. It's now approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors.